Navigation Links
Access Pharmaceuticals to Present at LifeTech Capital Miami Medical Investors Conference on November 12th
Date:11/9/2010

DALLAS and NEW YORK, Nov. 9, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that its Chairman, Steven Rouhandeh, will present at the 1st Annual LifeTech Capital Miami Medical Investors Conference on Friday, November 12, 2010, at 1:00 pm ET.  The conference is being held at the JW Marriot Marquis in Miami, Florida.

The LifeTech Capital Miami Medical Investors Conference will bring together promising biotechnology companies, medical and scientific key opinion leaders with institutional and accredited investors from across the country. More information can be found at www.LifeTechCapital.com/conference.

About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), for the management of patients with mucositis, ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company

Contact: Investor RelationsChristine Berni

Donald C. Weinberger/Diana Bittner (media)Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
2. Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
3. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
4. Access Pharmaceuticals Awarded $1.5 Million in Section 48D Grants
5. Access Pharmaceuticals Signs Agreement With Leading Biopharmaceutical Company to Develop CobOral™ Formulation of Widely-Marketed Injectable
6. Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases
7. The Development of Medical Foundations in the San Diego Area will Restrict Physician Access for Pharmaceutical Reps
8. Recent Patient Series Demonstrates Spirus Medicals Power Spiral Endoscope Enables Unprecedented Access to GI Tract
9. Utahs Seniors and People with Disabilities Will Feel Impact of Medicare Policy Changes that Restrict Access to Power Wheelchairs
10. Pemiscot Memorial Health Systems Selects ChartAccess® Comprehensive EHR From Prognosis Health Information Systems
11. Pioneer® Surgical Technology, Inc. Announces Agreement to Acquire Exclusive Access to the Cequence™ Cervical Plate System From SpineSmith, LP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... May 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it is teaming ... STI Technologies Limited to lower diabetes healthcare costs in ... innoviCares card, which is available throughout all provinces and ... will be eligible for additional savings when shopping for ...
(Date:5/3/2017)... 2017 A Catheterization Laboratory is an ... facility. Commonly referred to as cath lab, this ... imaging technology to give physicians visual access to ... spaces, a team of physicians perform life-saving procedures ... intervention, congenital heart defect closure, stenotic heart valves, ...
(Date:5/3/2017)... Pa. , May 3, 2017  West ... in innovative solutions for injectable drug administration, announced ... Scientific Affairs and Technical Services, and Diane ... workshops and offering presentations focused on West,s expertise ... injectable products, as well as providing commentary on ...
Breaking Medicine Technology:
(Date:5/26/2017)... MN (PRWEB) , ... May 26, 2017 , ... A ... U.S. states with the healthiest seniors are located in the Midwest. With the average ... more and more people are concerned with both the quality and affordability of where ...
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing ... blog post on insurance options. If a Bay Area patient has to search for ... and money. Visiting an in-network provider for a second opinion can ensure a patient ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “Just What Happened in the Garden of Eden”: ... the Garden of Eden” is the creation of published author, Penelope Colt, mother, trader, horse ... family moved to NYC when she was three. At six, they moved to Dayton, ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success ... appropriate instruments for research and understanding the basic principles that were designed to ... on innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories ...
Breaking Medicine News(10 mins):